Low-dose aspirin and risk of anaemia in older adults: insights from a Danish register-based cohort study
Authors' conclusion
These findings indicate that in a real-world setting, anaemia with LDA can occur in 6-10 older individuals out of every 100 LDA users during the first 5 years of treatment.
Study context
- Population
- Danish older individuals (≥65 years), low-dose aspirin (LDA) exposure 2008–2013 for primary or secondary CV prevention
- Participants
- 313,508 individuals
- Exposure
- Low-dose aspirin vs no low-dose aspirin
- LDAn = 59,869
- Non-users of LDAn = 253,639reference
- Outcome
- Anaemia incidence (haemoglobin values) and hematinic deficiency incidence (antianaemic prescriptions)
- Follow-up
- 5-year follow-up
Methodological detailsregister-based
- Register-based
Main finding
As reported in the abstract
LDA
- Hematinic deficiency (antianaemic treatment)
- 9.6%
- Anaemia (haemoglobin)
- 5.9%
Non-users of LDA
3.7%
Hematinic deficiency (antianaemic treatment)
LDA vs Non-users of LDAIncidence rate ratio (95% CI)
Hematinic deficiency
9.11(8.81–9.41)
Anaemia by haemoglobin
7.89(7.58–8.21)
Observational data: associations, not effects.
Further findings
Severe anaemia
Bleeding among those with anaemia
- Anaemia with bleeding (approximately one in five)
- n = 2 422, 21.5%
Haemoglobin and ferritin among exposed
- Reduction in haemoglobin and ferritin associated with anaemia severity
Original publication
Low-dose aspirin and risk of anaemia in older adults: insights from a Danish register-based cohort study. Eur Heart J Qual Care Clin Outcomes. Published 11 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →